{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:46Z","timestamp":1789958866994,"version":"4.0.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["756017"],"award-info":[{"award-number":["756017"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022852","name":"Centre for Air Pollution, Energy and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"HW & J. Hector Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bavarian Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["409510"],"award-info":[{"award-number":["409510"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008848","name":"Elite Network of Bavaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010138","name":"Fritz Bender Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"German Jos\u00e9 Carreras Foundation for Leucemia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055-2-1"],"award-info":[{"award-number":["KO5055-2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GO 3823\/1-1"],"award-info":[{"award-number":["GO 3823\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055\/3-1"],"award-info":[{"award-number":["KO5055\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["SFB-TRR 338\/1 2021\\u2013452881907"],"award-info":[{"award-number":["SFB-TRR 338\/1 2021\\u2013452881907"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101100460"],"award-info":[{"award-number":["101100460"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000783","name":"REA","doi-asserted-by":"publisher","award":["955575"],"award-info":[{"award-number":["955575"]}],"id":[{"id":"10.13039\/501100000783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.coph.2025.102524","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:12:20Z","timestamp":1744132340000},"page":"102524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Novel approaches to CAR T cell target identification in acute myeloid leukemia"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3167-2124","authenticated-orcid":false,"given":"Gordon Victor","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gottschlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102524_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102524_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"10.1016\/j.coph.2025.102524_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102524_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102524_bib5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102524_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102524_bib7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102524_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102713","article-title":"The black hole: CAR T cell therapy in AML","volume":"15","author":"Atilla","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2025.102524_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1085978","article-title":"Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia","volume":"13","author":"Schorr","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2025.102524_bib10","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","author":"Tur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2025.102524_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.coph.2025.102524_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102524_bib13","first-page":"2453","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity. 1975","volume":"174","author":"Kohler","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2025.102524_bib14","first-page":"251","article-title":"Monoclonal antibodies and cell surface antigens","author":"Milstein","year":"1979","journal-title":"Ciba Found Symp"},{"key":"10.1016\/j.coph.2025.102524_bib15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.4049\/jimmunol.128.2.876","article-title":"Normal and malignant human myelocytic and monocytic cells identified by monoclonal antibodies","volume":"128","author":"Bernstein","year":"1982","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2025.102524_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","article-title":"A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells","volume":"8","author":"Griffin","year":"1984","journal-title":"Leuk Res"},{"key":"10.1016\/j.coph.2025.102524_bib17","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2401907","article-title":"Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions","volume":"14","author":"Brendel","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102524_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133214","article-title":"CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2025.102524_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102524_bib20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102524_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102524_bib22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1470-2045(24)00014-7","article-title":"Antibody-drug conjugates in acute myeloid leukaemia: more research needed","volume":"25","author":"Kayser","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102524_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib24","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102524_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coph.2025.102524_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33 x CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.coph.2025.102524_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0609.1989.tb01203.x","article-title":"Sequential expression of CD34 and CD33 antigens on myeloid colony-forming cells","volume":"42","author":"Buhring","year":"1989","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.coph.2025.102524_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102524_bib30","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37,","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102524_bib32","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1073\/pnas.1902375116","article-title":"Heterogeneity in refractory acute myeloid leukemia","volume":"116","author":"Horibata","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2025.102524_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","article-title":"Genetic and epigenetic heterogeneity in acute myeloid leukemia","volume":"36","author":"Li","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.coph.2025.102524_bib34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2020006921","article-title":"CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy","volume":"137","author":"Willier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib36","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102524_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2025.102524_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030477","article-title":"Therapeutic strategies for targeting IL-1 in cancer","volume":"13","author":"Gottschlich","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2025.102524_bib39","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood.V97.11.3574","article-title":"High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)","volume":"97","author":"Baer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib40","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","article-title":"Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies","volume":"103","author":"Zha","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coph.2025.102524_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102524_bib42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41586-021-04109-7","article-title":"CRISPR screens unveil signal hubs for nutrient licensing of T cell immunity","volume":"600","author":"Long","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102524_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102524_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? Promises and pitfalls","volume":"56","author":"Cummins","year":"2019","journal-title":"Semin Hematol"},{"key":"10.1016\/j.coph.2025.102524_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-022-00390-4","article-title":"Integrated multiomic approach for identification of novel immunotherapeutic targets in AML","volume":"10","author":"Kohnke","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.coph.2025.102524_bib47","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2010-02-271270","article-title":"Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells","volume":"116","author":"Hofmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102524_bib48","doi-asserted-by":"crossref","first-page":"D881","DOI":"10.1093\/nar\/gky1076","article-title":"BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles","volume":"47","author":"Bagger","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coph.2025.102524_bib49","doi-asserted-by":"crossref","first-page":"D1034","DOI":"10.1093\/nar\/gks1021","article-title":"HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis","volume":"41","author":"Bagger","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coph.2025.102524_bib50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","author":"Consortium","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2025.102524_bib51","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin beta(2) as a CAR T cellular therapy target","volume":"4","author":"Mandal","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.coph.2025.102524_bib52","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.coph.2025.102524_bib53","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coph.2025.102524_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114260","article-title":"Immunotherapeutic targeting of surfaceome heterogeneity in AML","volume":"43","author":"Bordeleau","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2025.102524_bib55","article-title":"CRISPR screens in mechanism and target discovery for AML","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.coph.2025.102524_bib56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12943-024-01987-z","article-title":"Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies","volume":"23","author":"Xiang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.coph.2025.102524_bib57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102524_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102524_bib59","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","article-title":"Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells","volume":"38","author":"Volta","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102524_bib60","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102524_bib61","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:55:00Z","timestamp":1778813700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"alternative-id":["S1471489225000207"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102524","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel approaches to CAR T cell target identification in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102524"}}